A PHASE-II STUDY OF 5-FLUOROURACIL PLUS FOLINIC ACID IN MALIGNANT GLIOMAS IN ADULTS

Fourteen patients with malignant gliomas were entered on a phase II st udy of 5-fluorouracil 300-370 mg/m(2) plus folinic acid 200 mg/m(2) x 5 days q4 weeks. To be eligible, patients could not have received more than 1 prior chemotherapy regimen. A single patient with a recurrent oligodendroglioma responded. Toxicity (predominantly stomatitis, diarr hea, and granulocytopenia) was tolerable and was similar to that seen in studies of 5-fluorouracil plus folinic acid in other tumor types. T his regimen has minimal activity in recurrent malignant gliomas.